Clinical Research Details Clinical Research Study of BD ORC Original Absorbable Hemostat vs. Surgicel® Original Absorbable Hemostat Study Description This study will evaluate the safety and efficacy of BD ORC Original Absorbable Hemostat when compared to a currently marketed ORC hemostat (Surgicel® Original Absorbable Hemostat) for achieving hemostasis at target bleeding sites (TBSs) as an adjunctive hemostat in planned, open/minimally invasive general surgical procedures Inclusion/Exclusion Criteria Inclusion Criteria: 1. Males or females 22 years of age or older at the time of consent 2. Is undergoing a planned open/minimally invasive surgical procedure in general surgery Exclusion Criteria: 1. Is known to be pregnant or plans to become pregnant during the study period 2. Has an uncontrolled bleeding disorder 3. Has a documented clinical history of bleeding or coagulation disorder or disease 4. Has received hemodialysis within 30 days before surgery or is planned to receive hemodialysis within 45 days post-surgery 5. Has documented severe congenital or acquired immunodeficiency or is currently being treated with immunosuppressive drugs 6. Has been treated or is planning to be treated with another investigational drug or device within 30 days of surgery 7. Has taken blood thinners or chronic steroids Open Enrollment Contact Name: Tatiana Elias-GrajedaContact Phone: (904) 244-9687Contact Email: tatiana.elias-grajeda@jax.ufl.edu Investigators Timothy S. Hester, D.O., FACS, DABS Surgery Ruchir Puri, M.B.B.S. (M.D.), M.S., FACS Surgery Jana M. Sacco, M.D. Surgery